Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis. | Synapse
March 1, 2026
Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis.
Key Points
To assess the impact of resmetirom on health-related quality of life in patients with early MASH and MASH cirrhosis.
Analyzed health-related quality of life scores before and after resmetirom treatment.
Included patients across the spectrum of MAFLD from early MASH to MASH cirrhosis.
Evaluated disease-specific outcomes.
Patients experienced significant improvements in certain disease-specific HRQL scores after treatment with resmetirom.
Abstract
Early MASH and MASH cirrhosis treated with resmetirom experience improvement in some disease-specific HRQL scores.